At this stage, most patients report a noticeable reduction in hunger and cravings, helping them eat less and make healthier food choices
Similar content being viewed by others Introduction Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a persistent and debilitating medical condition, affecting around 1% of the population [1]
If Foundayo's clinical outcomes hold up in real-world use (the Phase 3 ATTAIN-1 trial showed 11.2% mean weight loss at 72 weeks on the 36 mg dose, or 12.4% among participants who stayed on treatment), it could become the go-to affordable GLP-1 option and put downward pressure on Wegovy and Zepbound pricing
Research suggests it can be used to explore epithelial barrier integrity, extracellular matrix remodeling, and cell migration in preclinical in-vitro and animal experiments
Oxid Med Cell Longev 2014:102158 Naughton P, Foresti R, Bains SK, Hoque M, Green CJ, Motterlini R (2002) Induction of heme oxygenase 1 by nitrosative stress
